Recursion (NASDAQ:RXRX) reported fourth-quarter 2025 revenue of $35.5 million on Wednesday, significantly exceeding analyst estimates of $24.6 million. The performance was driven by the timing of ...

The following slide deck was published by Recursion Pharmaceuticals, Inc. in conjunction with this event.

Creating simple data classes in Java traditionally required substantial boilerplate code. Consider how we would represent Java’s mascots, Duke and Juggy: public class JavaMascot { private final String ...

Today, a brief rundown of news involving Insmed and Recursion Pharmaceuticals, as well as updates from Odyssey Therapeutics, Gilead Sciences and Novo Nordisk that you may have missed. Expected ...

Recursion, a clinical-stage TechBio company, is set to present preliminary data from its Phase 1b/2 clinical trial, TUPELO, at the 2025 Digestive Disease Week (DDW) meeting on May 4, 2025, in San ...

The excessive uncertainty of in modern manufacturing systems is caused by machine failures, changes in material information, and other factors. In addition, the organizational production mode ...

Vibhas is a Software Development Manager at Amazon with over 12 years of industry experience in large scale distributed systems, databases and cloud native applications. Vibhas is a Software ...

SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced top-line results of ...